The market growth is attributed to the increasing adoption of this technology in the biopharmaceuticals industry and technological advancements in cleanrooms. However, high costs associated with cleanrooms restrict the cleanroom technology market growth in Europe.
Pharmaceuticals and biologics development and manufacturing processes need to comply with several local and international standards for product approvals. With the growing demand for therapeutic drugs and vaccines, biopharmaceutical and pharmaceutical companies have shifted their focus on escalating their production capacities. The demand for cleanrooms used in their production facilities continues to grow significantly with increasing concerns regarding contamination, regulatory challenges, and operational efficiencies. The production of antibody–drug conjugates, which are among the emerging biotherapeutics, requires a custom-made infrastructure to ensure strict compliance with the global regulatory standards. For instance, in 2019, WHP Engineering completed a new cleanroom facility for the Welsh manufacturing plant of ADC Bio, which is an antibody-drug conjugates producer. The good manufacturing practices (GMP) facility of the company delivers the next generation of the blockbuster anticancer drugs of ADC. Further, cell and gene therapies are among the rapidly expanding segments of the biotherapeutics industry. In December 2020, WHP completed a new viral vector manufacturing center for Oxford Biomedica. The new GMP facility is suitable for manufacturing vaccines and gene therapy products, and it will also be used for the large-scale manufacturing of the COVID-19 vaccine. The design includes cleanroom architecture; heating, ventilation, and air conditioning (HVAC); and process and critical utility systems. A surge in investments in pharmaceutical contract research, development, and manufacturing organizations (CDMOs) would also support the cleanroom technologies market growth.
Spain, Italy, Germany, France, and the UK are among the most affected European countries by the COVID-19 pandemic. The pandemic also led to the postponing of dates of introducing new regulations and guidelines from May 2020 to May 2021, which also affected the enactment of the upcoming European Union Medical Device Regulation (2017/745). In addition, the supply of important equipment and consumables reached stagnancy in 2020. Moreover, the dependency on suppliers from other countries lengthens the process of procurement of medical devices and related consumables. Therefore, several medical companies were not able to meet the demand for medical equipment and personal protective equipment across the countries.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,285.90 Million |
| Market Size by 2028 | US$ 2,041.61 Million |
| Global CAGR (2021 - 2028) | 6.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |